In the same study, the authors found that mutations in ctDNA of RB1 and EGFR could be used as biomarkers for predicting the IDH-wildtype subtype of GBM and, consequently, the malignancy of the tumour [40]. This evidence concerns the gene IDH1 and glioblastoma.